Novartis shares fall after weak Q1 hit by Entresto competition

Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugmaker declined about 3% in premarket trading on Tuesday following the earnings release.